In a retrospective study 89, 65 patients with unresectable, recurring, or metastatic CCA were selected to receive DC-based immunotherapy, and WT1 and/or MUC1 pulses were used to stimulate DC. The gene discussed is WT1; the disease is cholangiocarcinoma.